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Abstract
We have investigated the biochemical mechanism of tumor necrosis factor (TNF)-K-induced release of plasminogen
activator inhibitor-1 (PAI-1) from human umbilical vein endothelial cells (HUVEC). Treatment of HUVEC with TNF-K for
3 h resulted in a 2.8-fold increase in the PAI-1 release compared with control. The increase in PAI-1 release was accompanied
by a 133% increase in the intracellular acidic sphingomyelinase (SMase) activity. High-performance liquid chromatographic
(HPLC) analysis revealed that the intracellular ceramide levels increased to 126% of the control (P6 0.05), but the contents
of membranous ceramide remained unaltered. We have previously shown that a cell-permeable ceramide analog, N-
acetylsphingosine (C2-ceramide) enhances the PAI-1 release from HUVEC. Here, N-acetylsphinganine (C2-dihydroceramide)
was found to specifically suppress both C2-ceramide- and TNF-K-induced increase in PAI-1 release from HUVEC without
affecting the control PAI-1 release. Treatment of HUVEC with staphylococcal SMase that may mimic the activation of the
membranous neutral SMase also increased the PAI-1 release. The increase in PAI-1 release by this mechanism was
suppressed by a cyclooxygenase inhibitor, aspirin, whereas the inhibitor did not affect TNF-K-induced increase in PAI-1
release. Taken together, these findings suggest that TNF-K prominently utilizes the lysosomal acidic SMase-ceramide
signaling pathway in the induction of PAI-1 release from HUVEC. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Plasminogen activator inhibitor-1 (PAI-1) plays an
important role in the regulation of ¢brinolysis by
inactivating rapidly both tissue-type and urokinase-
type plasminogen activators [1,2]. Suppression of ¢-
brinolysis through the elevated levels of plasma PAI-
1 has been frequently found in coronary artery dis-
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ease patients [3,4]. The PAI-1 production by vascular
endothelial cells is increased by a number of cellular
stimuli including endotoxin [5], thrombin [6], lipo-
protein(a) [7], interleukin-1 [8] and tumor necrosis
factor-K (TNF-K) [9,10]. The concentration of plas-
ma PAI-1 is dramatically increased during endotox-
emia. Endotoxin can induce the release of TNF-K
from vascular endothelium. TNF-K thereafter indu-
ces tissue factor activity in the endothelial cells [11]
which leads to the generation of a PAI-1 stimulator,
thrombin [6], suggesting its key roles in the PAI-1-
related thromboembolic diseases.
TNF-K is known to interact with two distinct cell
surface receptors of 55 and 75 kDa, respectively, that
transmit signals down to the cytoplasm and nucleus
to initiate profound alterations of the transcriptional
programs [12]. Recently, several reports implicated
the lipid messenger ceramide in various important
pathways of TNF-K action [13]. In U937 cells,
TNF-K, through binding to the 55 kDa receptor,
rapidly activates two distinct types of sphingomyeli-
nases (SMases), a cell membrane-bound neutral
SMase and a lysosomal acidic SMase. Ceramide gen-
erated by the neutral SMase directs the activation of
proline-directed serine/threonine protein kinases and
phospholipase A2. In contrast, the acidic SMase trig-
gers the activation of NF-UB through the generated
ceramide [14].
We have previously shown that cultured human
umbilical vein endothelial cells (HUVEC) increase
the release of PAI-1 by being treated with staphylo-
coccal SMase or cell-permeable ceramide analogs,
such as N-acetylsphingosine (C2-ceramide) [15].
These results suggested a possible involvement of cer-
amide in the induction of PAI-1 release. The present
study was undertaken to investigate whether TNF-K
utilizes ceramide as a signaling molecule for the in-
duction of PAI-1 release. The results demonstrate
that ceramide, generated in endosomal/lysosomal
compartments, but not in cell membranes, may
play a prominent role in the TNF-K signaling.
2. Materials and methods
2.1. Materials
The following materials were commercially ob-
tained: C2-ceramide, Staphylococcus aureus SMase,
2-hexadecanoylamino-4-nitrophenylphosphorylcho-
line (HNP), ribonuclease A (RNase A) and protein-
ase K from Sigma; recombinant human TNF-K
(1.0U108 units/mg protein) from Boehringer Mann-
heim; C2-dihydroceramide from Biomol, Plymouth
Meeting, PA; aspirin from Wako, Osaka, Japan;
(+)-6-methoxy-K-methyl-2 naphthaleneacetic acid
(NAP), N,NP-dicyclohexylcarbodiimide (DCC) and
4-dimethylaminopyridine (DMAP) from Aldrich; as-
pirin from Wako, Osaka, Japan; 500 bp DNA ladder
from Takara Shuzo, Shiga, Japan.
2.2. HUVEC culture
HUVEC (passage 2) and the culture medium
EGM-MV were purchased from Sanko Junyaku, To-
kyo, Japan. The cells (6U105 cells) were plated into a
175-cm2 tissue culture £ask (Falcon) and grown to
near con£uency in EGM-MV (modi¢ed MCDB 131
medium that was supplemented with 5% fetal bovine
serum, 10 ng/ml epidermal growth factor, 1 Wg/ml
hydrocortisone, 50 Wg/ml gentamycin, 50 ng/ml am-
photericin B and 12 Wg/ml bovine brain extract) at
37‡C in a humidi¢ed 5% CO2 atmosphere. The me-
dium was renewed every 2 days. Subcultures were
obtained by treating the HUVEC cultures with
0.25% trypsin/0.01% EDTA (JRH, Lenexa, KS) at
37‡C for 5 min. All experiments were performed
with HUVEC in the 6th to 8th passages.
2.3. Treatment of HUVEC with various agents
The passaged cells were seeded at a density of
2.5U103 cells/cm2 onto collagen-coated 6-well tissue
culture plate in EGM-MV and allowed to reach con-
£uency. After removal of the conditioned media, the
HUVEC monolayers were rinsed twice with 2 ml of
Dulbecco’s modi¢ed Eagle’s medium (DMEM). The
HUVEC monolayers were then treated at 37‡C for
30 min with 3 ml of DMEM. After removal of
DMEM, incubation followed at 37‡C in 3 ml of
DMEM supplemented with or without the indicated
agent(s). Ceramide analogs were dissolved in ethanol,
and the other agents were in phosphate-bu¡ered sal-
ine (PBS). During treatment with these agents, con-
trol HUVEC were treated with an identical volume
of the vehicle. At de¢nite times, 100 Wl of the con-
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ditioned media was withdrawn and subjected to the
assay of PAI-1 antigen.
2.4. Assay of PAI-1 antigen
Antigen levels of PAI-1 in the conditioned media
were determined with an ELISA kit, Imulyse PAI-1
(Biopool, Umea«, Sweden), according to the manufac-
turer’s instructions.
2.5. Determination of cellular ceramide
Con£uent cultures of HUVEC in 175-cm2 tissue
culture £asks were rinsed with DMEM and incu-
bated at 37‡C for 30 min in 20 ml of DMEM. After
removal of the conditioned media, incubation fol-
lowed at 37‡C for 3 h in 20 ml of DMEM supple-
mented with or without TNF-K (200 U/ml). Each cell
culture was detached by treatment with 10 ml of
0.05% trypsin/0.53 mM EDTA (Gibco-BRL), and
pelleted by centrifugation. The pellet was washed
three times with 10 ml of cold PBS, and centrifuged
again. The washed cells (5U106) were resuspended in
220 Wl of cold PBS/0.25 M sucrose, transferred into a
microtube, and disrupted by sonication. After the
cell lysate was centrifuged at 800Ug for 10 min,
the supernatant (cytosol plus organelle fraction)
was withdrawn. The pellet was washed three times
with 1 ml of cold PBS, centrifuged, and suspended in
220 Wl of PBS (cell membrane fraction). The follow-
ing lipid extraction and ceramide determination in
each fraction were carried out according to the meth-
od of Previati et al. [16]. Brie£y, each fraction (200
Wl) was mixed with 4 ml of chloroform/methanol
(2:1) and extracted for 30 min. After the addition
of 1 ml of water, the sample was vortexed and cen-
trifuged. The lower phase was collected and evapo-
rated to dryness under a nitrogen stream. The resi-
due was dissolved in 100 Wl of chloroform, and the
solution was reacted at 320‡C for 3 h with 100 mM
NAP, 100 mM DCC and 100 mM DMAP (10 Wl
each). After evaporation of the solvent under a nitro-
gen stream, the residue was suspended in 15 Wl of
chloroform. The suspension was mixed with 2 ml
of hexane and centrifuged. The supernatant was vig-
orously mixed with 5 ml of methanol/water (4:1) and
centrifuged. A part (1 ml) of the upper phase was
collected and ¢ltered through a 0.45-Wm membrane
¢lter. The HPLC system consisted of a Model 600
solvent delivery system (Waters), a Model 474 £uo-
rescence detector (Waters) and a Model 805 data
station (Waters). A 20-Wl portion of the ¢ltrate was
injected into an Econosphere CN 5U column
(4.6U250 mm, Alltech). The derivatized ceramide
was separated from by-products with 3% 2-propanol
in n-hexane as the mobile phase. The £ow rate was
2.0 ml/min, and the e¥uent was monitored £uoro-
metrically at the excitation wavelength of 230 nm
and emission wavelength of 352 nm.
2.6. Determination of acidic SMase activity
The acidic SMase activity in HUVEC was deter-
mined photometrically with HNP as a substrate [17].
The fractions of cell membrane and cytosol plus or-
ganelles derived from TNF-K-treated or untreated
HUVEC were used as enzyme sources. Brie£y, the
assay mixture contained the following components in
a total volume of 100 Wl : 15 mM HNP, 250 mM
sodium acetate bu¡er (pH 5.6) containing 0.05%
Tween 80 and 50 Wl enzyme preparation. The enzyme
reaction was carried out at 37‡C and terminated with
400 Wl of 100 mM glycine bu¡er (pH 10.5) plus 700 Wl
ethanol. The tube was vortexed and centrifuged at
2000Ug for 10 min. The absorbance of the super-
natant solution was determined at 410 nm.
2.7. Assay of cell death and cell lysis
The lysis of HUVEC was measured with a com-
mercial cytotoxicity detection kit (Boehringer Mann-
heim). This assay method is based on the measure-
ment of lactate dehydrogenase (LDH) activity
released from the cytosol of damaged cells into the
supernatant.
2.8. Analysis of DNA fragmentation by agarose gel
electrophoresis
HUVEC (1U106 cells) were harvested and pelleted
by centrifugation at 400Ug for 5 min. The pellet was
washed with cold PBS and resuspended in 20 Wl of a
lysis bu¡er, 50 mM Tris-HCl bu¡er (pH 7.8)/10 mM
EDTA/0.5% sodium N-lauroylsarcosinate. To the
suspension was added 1 Wl of RNase A (10 mg/ml
in the lysis bu¡er) and incubation followed at 50‡C
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for 30 min. The reaction mixture was mixed with 1 Wl
of proteinase K (10 mg/ml in the lysis bu¡er) and
incubated again at 50‡C for 60 min. After centrifu-
gation, the nuclei sample was electrophoresed at
100 V on 1.5% agarose gel containing 0.5 Wg/ml ethi-
dium bromide. DNA was visualized under UV light
and photographed.
2.9. Statistical analysis of data
All values are expressed as the means þ S.D., and
the signi¢cant levels between groups were assessed by
Student’s t test.
3. Results
3.1. TNF-K-induced increase in PAI-1 release from
HUVEC is accompanied by an increase in
intracellular ceramide content and acidic SMase
activity
We ¢rst examined the e¡ect of TNF-K on PAI-1
release from HUVEC. TNF-K increased the PAI-1
release in a dose-dependent manner, and the maxi-
mal levels of PAI-1 (35.3 þ 1.00 ng/ml, a 2.8-fold in-
crease compared with control) were observed at a 3-h
incubation with 200 U/ml TNF-K. The leakage of
LDH activity from the TNF-K-treated HUVEC
was not di¡erent from the control level, suggesting
that the cytokine-inducible cellular lysis can be neg-
ligible (data not shown). Next, to determine whether
TNF-K could alter the cellular ceramide levels, con-
£uent cultures of HUVEC were treated for 3 h in
DMEM supplemented with or without TNF-K (200
U/ml) and then fractionated into cell membranes and
cytosol plus organelles, respectively (see Section 2).
As shown in Fig. 1A, TNF-K increased the net con-
tent of ceramide in the cytosol plus organelle fraction
to 126% of the control (639 þ 18. 3 ng vs. 803 þ 64.7
ng, P6 0.05). However, this cytokine did not alter
the membranous ceramide content, suggesting little
or no involvement of the activation of membranous
neutral SMase. On the other hand, there was a 33%
increase (P6 0.01) in the net activity of acidic SMase
(HNP hydrolysis at pH 5.6) present in the cytosol
plus organelles derived from TNF-K-treated HUVEC
(Fig. 1B). This result implies the possibility that
TNF-K may prominently activate the acidic SMase
located in endosomal/lysosomal compartments.
3.2. C2-dihydroceramide suppresses both C2-ceramide-
and TNF-K-induced increases in PAI-1 release
from HUVEC
Olivera et al. [18] previously demonstrated that
Fig. 1. E¡ect of TNF-K on the intracellular ceramide levels (A)
and acidic SMase activity (B) in HUVEC. Cultured HUVEC
were stimulated with TNF-K (200 U/ml) at 37‡C for 3 h, and
then the cells were harvested and fractionated as described in
Section 2. Ceramide levels were determined by a HPLC meth-
od. SMase activity was determined with HNP as the substrate.
Each bar represents the mean þ S.D. of triplicate experiments.
*P6 0.05; **P6 0.01, compared to control.
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staphylococcal SMase or cell-permeable ceramide
analogs, such as C2-ceramide, stimulated the prolif-
eration of Swiss 3T3 cells and suggested that ceram-
ide was involved in the cellular proliferation induced
by various growth factors. By using the same exper-
imental techniques, we also suggested the involve-
ment of ceramide in the induction of PAI-1 release
from HUVEC [15]. Fig. 2A and B show the concen-
tration-dependent e¡ects of C2-ceramide and SMase,
respectively, on the release of PAI-1 from cultured
HUVEC. By a 3-h incubation of HUVEC with 10 WM
C2-ceramide, the PAI-1 antigen level rose from
22.3 þ 0.25 to 47.3 þ 1.57 ng/ml (a 2.1-fold increase).
The treatment of HUVEC for 3 h with 0.2 U/ml
SMase caused a nearly maximal e¡ect on the PAI-1
release, and the increased PAI-1 antigen levels were
3.1-fold the control level (16.2 þ 0.95 ng/ml). How-
ever, the leakage of LDH activity from the HUVEC,
treated for 3 h with 10 WM C2-ceramide or 0.2 U/ml
SMase, was similar to that of control (data not
shown). We also examined the e¡ect of C2-ceramide
on the internucleosomal DNA fragmentation in
HUVEC to know whether the C2-ceramide-induced
PAI-1 release was due to the results from its leakage
followed by apoptosis. The cells were incubated for
3^24 h in DMEM supplemented with or without C2-
ceramide. The genomic DNA of HUVEC was not
a¡ected by a 3-h incubation with either 10 or
20 WM C2-ceramide, although at a 24-h incubation
the DNA fragmentation was more clearly observed
in C2-ceramide-treated HUVECs (data not shown).
Therefore, these ¢ndings indicate that the increase in
PAI-1 release at 3 h is not due to the results from
cellular lysis or apoptosis in HUVEC by the agent,
suggesting the primary role of C2-ceramide as a lipid
messenger for the PAI-1 production.
Fig. 2. Concentration-dependent e¡ect of C2-ceramide (A) or
staphylococcal SMase (B) on the release of PAI-1 antigen from
cultured HUVEC. Con£uent cultures of HUVEC (1U106 cells)
were incubated at 37‡C for 3 h in DMEM supplemented with
the indicated concentrations of C2-ceramide or SMase. Each
bar represents the mean þ S.D. of triplicate experiments.
Fig. 3. (A) E¡ect of C2-dihydroceramide on the C2-ceramide
(or SMase)-induced increase in PAI-1 release. Con£uent cul-
tures of HUVEC (1U106 cells) were incubated at 37‡C for 3 h
in DMEM supplemented with or without the indicated concen-
trations of agents. (B) E¡ect of C2-dihydroceramide on the
TNF-K-induced increase in PAI-1 release. Cultured HUVEC
were stimulated with TNF-K (200 U/ml) at 37‡C for 3 h in the
presence or absence of the indicated concentrations of C2-dihy-
droceramide. Each bar represents the mean þ S.D. of triplicate
experiments. *P6 0.05, compared to control (or TNF-K alone).
C2-cer, C2-ceramide; Dcer, C2-dihydroceramide.
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During the experiments that have examined the
concentration-dependent e¡ects of C2-ceramide and
SMase on the PAI-1 release (Fig. 2A,B), we found
that 20 WM C2-ceramide and SMase (0.2 U/ml) in
combination could synergistically increase the PAI-
1 release from 51.1 þ 1.64 to 72 þ 2.76 ng/ml (data
not shown). This ¢nding suggested a possibility
that ceramide generated by staphylococcal SMase
at plasma membrane and C2-ceramide incorporated
into the cells might utilize di¡erent signal transduc-
tion pathways. To determine this possibility, experi-
ments were undertaken to examine the e¡ect of C2-
dihydroceramide on the C2-ceramide- or SMase-in-
duced PAI-1 release from HUVEC, since C2-dihy-
droceramide di¡ers from C2-ceramide only in that
it lacks the 4,5 trans double bond and has no C2-
ceramide-like activity. As shown in Fig. 3A, C2-dihy-
droceramide e¡ectively suppressed the C2-ceramide-
induced increase in PAI-1 release to near the control
levels (control, 15.8 þ 2.63 ng/ml vs. C2-ceramide plus
C2-dihydroceramide, 21.1 þ 3.65 ng/ml). However,
the PAI-1 release was not a¡ected by this compound
alone (15.9 þ 1.13 ng/ml). C2-dihydroceramide had
little or no e¡ect on the SMase-induced increase in
PAI-1 release (SMase alone, 67.2 þ 9.13 ng/ml vs.
SMase plus C2-dihydroceramide, 64.4 þ 14.8 ng/ml).
We next examined the e¡ect of C2-dihydroceramide
on TNF-K-induced increase in PAI-1 release (Fig.
3B). C2-dihydroceramide at 6.5^25 WM signi¢cantly
suppressed the TNF-K-induced PAI-1 release in a
concentration-dependent manner (TNF-K alone,
31.3 þ 2.29 ng/ml vs. TNF-K plus 25 WM C2-dihydro-
ceramide, 18.9 þ 1.78 ng/ml, P6 0.05). Higher con-
centrations of C2-dihydroceramide (50 WM) did not
cause a further increase in the suppressive e¡ect (data
not shown). This ¢nding indicates that C2-dihydro-
ceramide competes with the incorporated C2-ceram-
ide for the induction of PAI-1 and additionally that
it could also compete with the intracellular ceramide
generated by acidic SMase after induction by TNF-K
(Figs. 1B and 2A).
To further con¢rm this possibility, we next at-
tempted to use a cyclooxygenase inhibitor, aspirin,
for the inhibition of TNF-K-induced PAI-1 release
from HUVEC. Treatment of HUVEC with staphy-
lococcal SMase that mimics the action of neutral
SMase may hydrolyze the membrane SM to ceram-
ide and phosphocholine. The membrane ceramide
signal transduction pathway may direct the activa-
tion of proline-directed serine/threonine protein ki-
nases and phospholipase A2 [14]. The activation of
phospholipase A2 could generate prostaglandins via
activation of cyclooxygenase. As shown in Fig. 4A,
C2-ceramide-induced increase in PAI-1 release was
not a¡ected by the clinically useful concentrations
of aspirin (28.4 þ 3.59 ng/ml vs. 26.8 þ 2.06 ng/ml).
However, the presence of 5 or 20 Wg/ml aspirin de-
creased SMase-induced PAI-1 release to the control
levels (control, 16.0 þ 0.51 ng/ml vs. SMase plus
20 Wg/ml aspirin, 17.9 þ 0.72 ng/ml). Additionally,
5 or 20 Wg/ml aspirin had no e¡ect on the TNF-K-
induced PAI-1 release from HUVEC (Fig. 4B). These
results indicate that the cyclooxygenase inhibitor as-
pirin speci¢cally suppresses staphylococcal SMase-in-
duced increase in PAI-1 release from HUVEC, but
neither TNF-K- nor C2-ceramide-induced increase is
Fig. 4. (A) E¡ect of aspirin on the C2-ceramide (or SMase)-in-
duced increase in PAI-1 release. Con£uent cultures of HUVEC
(1U106 cells) were incubated at 37‡C for 3 h in DMEM sup-
plemented with or without the indicated concentrations of
agents. (B) E¡ect of aspirin on the TNF-K-induced increase in
PAI-1 release. Cultured HUVEC were stimulated with TNF-K
(200 U/ml) at 37‡C for 3 h in the presence or absence of the in-
dicated concentrations of aspirin. Each bar represents the
mean þ S.D. of triplicate experiments. *P6 0.05, compared to
SMase alone. C2-cer, C2-ceramide.
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a¡ected, suggesting a possible role of intracellular
ceramide in the TNF-K signaling.
4. Discussion
In the present work, we indicate the possibility
that the lysosomally generated ceramide-mediated
signal transduction pathway(s) is involved in TNF-
K-induced increase in PAI-1 release from HUVEC.
This conclusion is based on the following observa-
tions. First, addition of TNF-K prominently in-
creased the intracellular ceramide levels in HUVEC,
but did not alter the membranous ceramide content
(Fig. 1A). Second, the increase in PAI-1 release was
accompanied by a signi¢cant activation of the intra-
cellular acidic SMase (Fig. 1B). Third, C2-dihydro-
ceramide, a derivative of C2-ceramide, suppressed the
increase in PAI-1 release induced not only by the
cell-permeable ceramide analog (Fig. 3A), but also
by TNF-K (Fig. 3B). C2-dihydroceramide failed to
suppress the increase in PAI-1 release induced by
staphylococcal SMase (Fig. 3A), while aspirin was
found to selectively suppress the increase in PAI-1
release induced by the SMase, but not by TNF-K
(Fig. 4A,B).
However, the increase in the intracellular ceramide
levels observed after TNF-K stimulation was signi¢-
cant, but very small (26% increase). The kinetics of
ceramide formation in response to TNF-K are very
di¡erent in di¡erent studies. TNF-K appears to in-
duce prolonged and persistent accumulation of cer-
amide that occurs over a period of several hours,
but serum withdrawal from culture medium also af-
fects the ceramide accumulation [19]. In this study,
the exchange of EGM-MV for serum-free DMEM
may have resulted in an increase in the ceramide
levels of control cells.
When considering the role of ceramide in the sig-
nal transduction, the most important thing is that
where, but not how much, the intracellular lipid me-
diator was generated. The increased ceramide is
probably due to the hydrolysis of SM by lysosomal
acidic SMase (TNF-K induced a 33% increase in ac-
tivity). The lysosomally generated ceramide might
induce a signal for the production of PAI-1. How-
ever, Slowik et al. [20] reported that the treatment of
HUVEC with TNF-K did not alter the intracellular
ceramide and SM levels, but activated NF-UB. This
suggests that TNF-K does not activate the SMase-
ceramide signaling pathway in HUVEC. One of the
reasons by which these contradicting results occurred
may be due to the di¡erence in culture conditions.
Although we cultivated HUVEC in MCDB 131 sub-
stituted with 5% serum and supplements, such as
epidermal growth factor, hydrocortisone, and bovine
brain extract prior to the experiments with serum-
free DMEM, they used a medium 199 supplemented
with 20% serum. Since there is a report that describes
acute changes in intracellular ceramide levels caused
by changes in culture conditions [21], preactivation
of HUVEC with di¡erent supplements could account
for the di¡erent results. Additionally, we used a high-
er concentration of TNF-K (200 U/ml) in our experi-
ments as compared to 100 U/ml used by Slowik et al.
[20]. The di¡erence in dose of TNF-K does not ac-
count for the di¡erent results, since 100 U/ml of
TNF-K induced PAI-1 to near the maximal level in
our experiments (a 2.5-fold increase, data not
shown).
A 3-h treatment of HUVEC with 10 WM C2-cer-
amide induced a 2.1-fold increase in PAI-1 release
(Fig. 2A). However, TNF-K increased PAI-1 release
by 2.8-fold in spite of a small increase in the intra-
cellular ceramide levels (approx. 200 ng/5U105 cells).
This discrepancy may be explained as follows. First,
the added C2-ceramide does not seem to be perfectly
incorporated into the cells. Second, since the alkyl
chain length of C2-ceramide is extremely short, it
may be unable to act as fully as the intracellular
ceramides. Additionally, 10 WM C2-ceramide and
TNF-K (200 U/ml) in combination did not a¡ect
the sole e¡ect of TNF-K on PAI-1 production
(data not shown), suggesting that both inducers uti-
lize the same signal transduction pathway.
Endogenous dihydroceramide is rapidly converted
to ceramide by the desaturase(s) present in the site of
microsomes [22]. In our system, however, C2-dihy-
droceramide still had the suppressive e¡ect over 6 h
(data not shown), suggesting that it was hardly con-
verted to C2-ceramide. Michel et al. [23] have clearly
demonstrated the in vitro conversion of dihydrocer-
amide to ceramide, using rat liver microsomes. They
have shown that the desaturase activity is in£uenced
by the alkyl chain length of the sphingoid base (in
the order C18sC12sC8). This ¢nding allowed us to
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speculate that the acetyl group of C2-dihydrocer-
amide might be too short for the binding to dihydro-
ceramide desaturase(s) in HUVEC. Ceramide gener-
ated by SM breakdown at the site of plasma
membrane is proposed to select major signaling path-
ways such as phospholipase A2, and proline-directed
serine/threonine-speci¢c protein kinases that include
CAPK and MAPK [14]. The activation of phospho-
lipase A2 may couple to cyclooxygenase activation
that is capable of generating prostaglandins. We
showed that aspirin, a speci¢c inhibitor of cycloox-
ygenase, e¡ectively suppressed the induction of
HUVEC PAI-1 release by staphylococcal SMase,
but neither by C2-ceramide nor by TNF-K (Fig.
4A,4B). This suggests that the cyclooxygenase has a
key role in mediating the staphylococcal SMase
(plasma membrane-associated neutral SMase)-in-
duced signaling cascade for PAI-1 release. After in-
duction by TNF-K, failure to determine the increase
in membranous ceramide level suggests little or no
involvement of the activation of neutral SMase in
HUVEC. If the so-called 55 kDa TNF-K receptor
contributes to the PAI-1 induction, it might simulta-
neously trigger the neutral SMase-ceramide signaling
pathway [14]. In this regard, Marathe et al. [24] have
reported that HUVEC is a rich and regulatable
source of secretory SMase and that when HUVEC
are incubated with interleukin-1L or interferon-Q, the
secretion of SMase is increased 2^3-fold compared
with the control. Interleukin-1L is known to promote
the release of PAI-1 from HUVEC [8]. It is not
known why interferon-Q does not induce the PAI-1
release in spite of its close relation with the SM cycle.
They also suggested that the secretory SMase was a
gene product of the lysosomal acidic SMase. In the
present work, we did not determine the secretion of
SMase from HUVEC. However, these ¢ndings imply
that SMase(s) arising from the acidic SMase gene
may play prominent roles in the cytokine-associated
ceramide signaling events in HUVEC. Thus, the ly-
sosomal/endosomal SMase-ceramide signaling path-
way appears to have a prominent role in the mech-
anism of TNF-K-induced PAI-1 release from
HUVEC, although there is evidence against the in-
volvement of lysosomal acidic SMase in TNF-K-in-
duced signaling in human ¢broblasts [25,26].
One could speculate on the pathophysiological re-
lationship between TNF-K-induced activation of ly-
sosomal SMase and PAI-1 release in vascular endo-
thelial cells. Products of the acidic SMase gene may
be implicated not only in ceramide-mediated cellular
di¡erentiation or apoptosis, but also in early athero-
genic processes. The secreted SMase may hydrolyze
lipoprotein SM to lipoprotein ceramide that leads to
the protein aggregation [27] and retention onto arte-
rially derived matrix [28]. The aggregation may lead
to induction of macrophage cholesteryl ester accu-
mulation [27,28]. On the other hand, intracellular
ceramide generated by lysosomal acidic SMase could
induce PAI-1 release. The secreted PAI-1 is accumu-
lated in the extracellular matrix [29], where it may
protect matrix components from proteolysis by limit-
ing plasmin generation. In spite of the pathological
role of plasma PAI-1 in coronary artery disease [3,4],
the PAI-1 function may be important to preserve the
integrity of the endothelium elements. Therefore, to
understand further the atherogenic processes, studies
addressing the roles of PAI-1 pathophysiologically
deposited into vascular endothelium and the regula-
tory mechanism of ceramide-induced PAI-1 will
hereafter be needed. The action of C2-dihydrocera-
mide presented here give us a hint that may lead to
improved methods for controlling PAI-1 that in-
creases the risk for atherosclerosis and thrombosis.
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